Global Genomics Leader Acquires Proteomics Platform with $450 Billion Cash Bet

Illumina, Inc. (NASDAQ: ILMN) on January 30 completed its acquisition of SomaLogic and certain assets of Standard BioTools, finalizing an agreement to pay $350 million in cash upfront and up to an additional $75 million based on future performance. The deal brings SomaLogic’s proteomics technologies—its SomaScan assay and SomaSignal tests—into Illumina’s next-generation sequencing platform, DRAGEN software, and Connected Multiomics, significantly boosting the company’s proteomics and multiomics capabilities. (investor.illumina.com)

On February 5, Illumina published its fourth-quarter and full-year 2025 results and announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted insurance coverage, effective January 1, for its TruSight Oncology Comprehensive cancer genomic test. The company also launched the large-scale gene perturbation dataset “Illumina Billion Cell Atlas” in collaboration with AstraZeneca, Merck, Eli Lilly and others, as it expands into clinical and AI-driven drug development. Additionally, Illumina plans to continue engaging with investors and the broader market by hosting a live discussion at the TD Cowen Annual Healthcare Conference on March 3. (investing.com)

Illumina is a global leader in next-generation sequencing instruments and reagents, widely used not only for research but also in cancer diagnostics and precision medicine. By acquiring SomaLogic, the company is executing a strategy to broaden its portfolio from genomics into the rapidly growing proteomics and multiomics markets, reinforcing its position as a data-driven healthcare platform. (investor.illumina.com)